Federal Circuit Rules For Bristol-Myers In Repligen Patent Suit
The decision affirms a lower court’s ruling in favor of Bristol-Myers Squibb.
In August 2002, Repligen filed a patent lawsuit against Bristol-Myers Squibb in the U.S. District Court for the Eastern District of Michigan. Repligen said it is the exclusive licensee of all patent rights to CTLA4-Ig, which is owned...
To view the full article, register now.